Population Monitoring of SARS-CoV-2 Infections via Random Sampling During the COVID-19 Pandemic.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Effect of anti-S antibody titers on newly confirmed cases of COVID-19 in Korea: a community-based cohort study (K-SEROSMART Wave 2).BMC infectious diseases · 2025
   Article
2. Chronic fatigue and headache in post-COVID-19 syndrome: a radiological and clinical evaluation.Frontiers in neurology · 2024
   Article
3. SARS-CoV-2 rapid antibody test results and subsequent risk of hospitalisation and death in 361,801 people.Nature communications · 2023
   Article
4. Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-SEROSMART): findings from national representative sample.Epidemiology and health · 2023
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as